Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How do drug companies set prices and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? And how can an industry that produces life saving drugs have a poorer public reputation than gun and tobacco industries that produce products that kill? Ed Schoonveld, a leading expert and consultant in global pharmaceutical pricing and market access issues, explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. His insights will help a wide range of audiences from healthcare industry professionals to policy makers and the broader public to gain a better understanding of this highly complex and emotionally charged field. "The Price of Global Health" is the first book of its kind: an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much needed and invaluable resource for anybody interested, involved in or affected by the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development, including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs.
Introduction; Part A Drug Pricing and Market Access Basics: The drug pricing challenge; Payers; Fundamentals of pricing; Reference based pricing; Health outcomes and health economics; Features, benefits, value and price.; Part B Structured P&MA Approaches: Pricing and drug development; Global payer segmentation; Key situation factors, the PODIUM approach; The Best Price framework to pricing and market access.; Part C Developing an Integrated Global Strategy: Corporate pricing and market access function; Developing a global pricing strategy; Public policy and ethical considerations; Risk sharing and alternative pricing schemes; Pricing research.; Part D Key Healthcare Systems: United States; Canada; France; Germany; Italy; Spain; UK; Japan; Australia; Brazil; China; India; References; Index.
(0 Comentarios)
